About Stem Cell

Regenerative Medicine is a paradigm shifting technology that will revolutionize global healthcare by curing or effectively treating the -patients- devastating acute and chronic diseases and conditions instead of the conventional medical options of treating the symptoms.


Regenerative medicine is a multidisciplinary field that combines the specialization of cellular, stem cell and developmental biology, tissue engineering, biochemistry, immunology, and other related disciplines that integrate to regeneratdamaged tissues and organs through various delivery, communication and signalling mechanisms that repair previously irreparable tissue and organs into healing and the restoring lost function and health.


Chronic diseases - such as heart    disease, cancer, and diabetes - are the leading causes of death and disability in the United States. These diseases account for 7 of    every 10 deaths and affect the quality of life of 133 million Americans – almost 1 out of every 2 adults – had at least one chronic illness. CDC Center for Disease Control and Prevention


Healthcare expenditures have grown more than twice the pace of the national gross domestic product (GDP), with nearly 75 cents of every healthcare dollar is (75%) spent on treatment of chronic diseases. Chronic diseases are No. 1 cause of death, illness, hospitalization, health care costs and long-term disability. Chronic disease affects every nation’s businesses and economy, reducing productivity    and placing an unsustainable burden on all sectors of society.


Can we reverse this devastating and unsustainable trend?  Yes we will.


Time is fast running out when we combine the increasing demographic tsunami of a rapidly aging population in industrialized countries with the costs of healthcare-for chronic diseases alone-that have grown to unprecedented levels. a fact emerges that is so evident that it cannot be debated or refuted is that maintaining the current healthcare system could well bankrupt the largest economies in the world.


It is this critical certainty of the healthcare dilemma for all people of the world; Regenerative Medicines potential to transform healthcare for all humanity should make it a priority at all healthcare levels; its relevance must be prioritized in the best interests of the economy, and contemporary society of every country.


iHorus/AppliCell members and our partners are impelled by these challenges to stand togetherto revolutionize healthcare through regenerative    medicine . 


What is the potential of tissue engineering regenerative medicine ? 

Dr. Alan Russell the chairman of our scientific board speaks at the TED Talks conference on the potential of regenerative medicine.



i-Horus Groupは,患者の自己修復能力である幹細胞に着目し、まだ、目覚めていない幹細胞を目覚めさせ(増殖)移植する方法を長年研究開発し治療のお手伝いをしてきたGroupです。





1、2003年 世界初、骨髄細胞を使用した心臓バイパス手術に成功。

2、2004年 世界初、骨髄細胞を使用した心筋症の治療に成功。

3、2005年 世界初、突発性心筋症の心臓移植の必要な患者に対するドナー細胞移植治療に成功。

4、2011 年 世界初、グロースファクタースプレーを使用した心臓治療に成功。


現在、当社は、心臓移植が必要 でありながら諸事情により心臓移植を受けることのできない心臓病患者9名にたいして、細胞(ドナー細胞)移植による治療に成功し、 現在、術語8年を経過しましたが、心臓移植とは異なり免疫抑制剤を使用する必要もなく、6名は健在でありお幸せに、ご家庭で過ごされております。


IHorus Inc, founders pioneered minimally invasive stem cell injections for CHF, and further advanced the clinical therapeutic benefit for late stage
CHF patients by utilizing potent HFDSCs early hematopoietic stem cell linesin 2005.

1、Argentina, March 2003: First autologous SC implant in OPCABG.

2、Uruguay, March 2004: First autologous SC implant in Idiopathic Cardiomyopathy.

3、Ecuador, July 2004: First autologous SC implant in OPCABG.

4、Ecuador, January 2005: First HFDSC implant in Idiopathic Cardiomyopathy.

5、Greece, July 2005: First autologous SC implant in Idiopathic Cardiomyopathy.